AbbVie Inc.
ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat aā¦ read more
Healthcare
Drug ManufacturersāGeneral
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$186.39
Price-2.68%
-$5.13
1Y
Price
Market Cap
$329.239b
Large
Price/Earnings 3y Avg5y Avg
79x
Premium
Premium
Dividends
Ex-Dividend: July 15, 253.52%
Yield$6.56
Dividend-0.61%
Forward Dividend Growth 3y CAGR5y CAGR
-0.6%
Premium
Premium
Payout Payout 3yPayout 5y
278.0%
Premium
Premium
Yield
BenchmarkDividends
No items found.
Financials Overview
Key metrics over the past few years+28.0%
EBITDA Margin+9.6%
Net Profit Margin+10.5%
Free Cash Flow MarginRevenue
$57.367b
+1.8%
1y CAGR-0.3%
3y CAGR+0.6%
5y CAGREarnings
$4.195b
-1.9%
1y CAGR-24.3%
3y CAGR-17.6%
5y CAGREPS
$2.36
-1.3%
1y CAGR-24.1%
3y CAGR-17.4%
5y CAGRBook Value
$1.462b
$136.165b
Assets$134.703b
Liabilities$69.889b
DebtDebt to Assets
51.3%
4.3x
Debt to EBITDAFree Cash Flow
$15.385b
-13.7%
1y CAGR-14.0%
3y CAGR-7.9%
5y CAGRFinancial Reports
Earnings and other important metricsNo items found.
Press Releases
Statements and updates from the company